Educational information, not medical advice — ask your doctor or midwife.
Track Juzentaihoto (Kampo) with reminders and record whether it helped, in the app.
Juzentaihoto is a traditional Kampo formula made up of exactly ten herbs, each chosen to work together to replenish both 'qi' (vital energy) and 'blood' according to East Asian medicine. It has been used in Japan and China for over a thousand years to help people recover from prolonged illness, surgery, or physical depletion. Today it is one of the most widely studied Kampo formulas in modern oncology and integrative medicine research.
The formula works through several complementary pathways at once. Some of its herbs — like astragalus and ginseng — support immune cell activity and help the body defend itself, while others like rehmannia and angelica are traditionally used to nourish and rebuild blood. Together, the blend is thought to help the body manage stress, reduce inflammation, support bone marrow recovery after chemotherapy, and restore overall vitality.
In Japan, standardized granule extracts (most commonly Tsumura TJ-48) are the dominant form and are covered by national health insurance for certain indications. Traditional preparation involves simmering the whole herbs as a decoction. Tablets and encapsulated extracts are available internationally for general wellness use.
Originally documented in the Chinese medical classic 'Taiping Huimin Heji Jufang' during the Song Dynasty (around 1107 CE), the formula was adopted into Japanese Kampo practice centuries later. It became a staple treatment for patients weakened by chronic illness, blood loss, or long winters. In modern Japan it is one of the few Kampo formulas that has been studied in formal clinical trials for cancer-related fatigue and immune support.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
Reviewed by the HealisticMD editorial team How we grade evidence →
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.